Crossmark

Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies

Crossref DOI link: https://doi.org/10.1007/s10067-018-4133-z

Published Online: 2018-05-15

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fabiani, Claudia

Sota, Jurgen

Rigante, Donato

Vitale, Antonio

Emmi, Giacomo

Lopalco, Giuseppe

Vannozzi, Lorenzo

Guerriero, Silvana

Bitossi, Alice

Orlando, Ida

Franceschini, Rossella

Frediani, Bruno

Galeazzi, Mauro

Iannone, Florenzo

Tosi, Gian Marco

Cantarini, Luca https://orcid.org/0000-0002-7352-1275
License Information

Text and Data Mining valid from 2018-05-15
More Information

Article History

Received: 29 March 2018

Accepted: 1 May 2018

First Online: 15 May 2018

Compliance with ethical standards

: The study was conducted according to the Declaration of Helsinki and all recruited patients had provided a written informed consent for critical evaluation of their clinical histories and medical charts.

: None.